A Study of Human TH-SC01 Cell Injection for Treating Perianal Fistulas in Patients With Crohn's Disease

Crohn's Disease Clinical Trial

Official title:

A Phase I Study to Evaluate the Safety and Tolerability of Human TH-SC01 Cell Injection for the Treatment of Perianal Fistulas in Crohn's Disease

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05626023
• Other study ID #: TH-SC 2.0
• Status: Not yet recruiting
• Phase: Phase 1/Phase 2
• Start date: November 30, 2022
• Est. completion date: December 30, 2023

Study information

• Verified date: November 2022
• Source: Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
• Contact: Zhaoshen Li, Dr.
• Phone: 021-81873241
• Email: zhaoshen-li[@]hotmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and tolerability of human TH-SC01 cell injection for the treatment of perianal fistulas in Crohn's Disease

Description:

This study is a phase 1, single-arm, safety and tolerability study of human TH-SC01 cell injection for perianal fistulas in Crohn's Disease.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 9
• Est. completion date: December 30, 2023
• Est. primary completion date: July 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Signed informed consent.

2. Subjects with Crohn's disease diagnosed at least 6 months earlier according to the Chinese Consensus Opinion on the Diagnosis and Treatment of Inflammatory Bowel Diseases (Beijing, 2018).

3. Subjects with active perianal fistula and non active luminal CD defined by a CDAI = 200.

4. Subjects with perianal fistula confirmed by clinical assessment and MRI.

5. Subjects aged between 18 and 70, both male and female.

6. All subjects and their partners were not planning to have a child from screening to the end of the trial and agreed to use effective non-drug contraception during the trial.

7. Subjects failed to respond to adequate treatment with any of the conventional antibiotics, immunomodulatory drugs (including steroids), anti-tumor necrosis factor-a (TNF-a) monoclonal antibodies and other biological agents.

Exclusion Criteria:

1. Subjects with active infection evaluated by the investigator.

2. Subjects with Crohn's disease requiring immediate therapy.

3. Subjects with abscess or collections >2 cm.

4. Subjects with rectal and/or anal stenosis and/or active proctitis.

5. Subjects who treated with systemic steroids in the 4 weeks prior to stem cells administration.

6. Subjects with abnormal laboratory results: liver function: total bilirubin >=1.5 × ULN, and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) >=2 × ULN; renal function: creatinine clearance below 60 mL/minute calculated using Cockcroft-Gault formula or by serum creatinine >=1.5 × upper limit of normal (ULN).

7. Subjects with malignant tumors or a history of malignant tumors.

8. Subjects with severe, progressive, uncontrolled hepatic, hematological, gastrointestinal (except Crohn's disease), endocrine, pulmonary, cardiac, neurological, psychiatric, or cerebral diseases.

9. Serum virology test (HBeAg, HCV antibody, HIV antibody, Treponema pallidum antibody) positive.

10. Subjects allergic to gentamicin sulfate, anesthetics or contrast media.

11. Subjects allergic to MRI contrast.

12. Subjects who has received stem cells in a previous clinical study or as a therapeutic agent.

13. Subjects who has major surgery or severe trauma within 6 months prior to the screening period.

14. Subjects who has received any investigational drug within 3 months prior to the screening.

15. Subjects deemed inappropriate by the investigator to participate in this clinical trial.

16. The female participant who is pregnant, or is lactating.

Related Conditions & MeSH terms

• Crohn Disease
• Crohn's Disease
• Fistula
• Perianal Fistula
• Rectal Fistula

Intervention

Drug:
• Human TH-SC01 cell injection
Single injection of human TH-SC01 cell injection

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Jiangsu Topcel-KH Pharmaceutical Co., Ltd.	Changhai Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Severity and incidence of adverse events	Severity and incidence of adverse events within 28 days after adiministration	28 days
Primary	Dose-limiting toxicity (DLT)	Exploration of dose-limiting toxicity (DLT)	84 days
Primary	Maximum tolerated dose (MTD)	Exploration of maximum tolerated dose (MTD)	84 days
Secondary	Perianal fistula healing	Change from baseline in Van Assche Score by MRI test. The score range was from 0 to 25. Higher score means more severe disease.	84 days
Secondary	Crohn's Disease Activity Index (CDAI) score	Change from baseline in the Crohn's Disease Activity Index (CDAI) score. Higher score means more severe disease and especially severe disease was defined as a value of greater than 450.	84 days
Secondary	Perianal Disease Activity Index (PDAI)	Change from baseline in Perianal Disease Activity Index (PDAI). Total score ranges from 0 to 20. Higher score means more severe disease.	84 days
Secondary	Inflammatory Bowel Disease Questionnaire(IBDQ)score	Change from baseline in IBDQ score. Total score ranges from 32 to 224. Higher score means better quality of life.	84 days
Secondary	VAS score	Change from baseline in pain score (VAS score).Total score ranges from 0 to 10. Higher score means more pain.	84 days
Secondary	Anal sphincter function:Wexner incontinence score	Change from baseline in anal sphincter function, Wexner incontinence score,Total score ranges from 0 to 20. Higher score means more severe disease.	84 days
Secondary	Anal sphincter function: rectal pressure	Change from baseline in rectal pressure,In healthy people, the pressure ranges from 60 to 150mmHg, with the internal sphincter pressure accounts for about 80% and external sphincter pressure accounts for 20%.	84 days